Obviously, avoidance of SGLT2 inhibition in this setting has changed with the trial data detailed above demonstrating clear benefits for both kidney and cardiac outcomes in people with CKD, regardless of diabetes status. This evidence concerns the gene SLC5A2 and diabetes mellitus.